Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.60 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | LSS | P48449 | 2/20 | 0.54 |
| ▸ | CHKA | P35790 | 1/20 | 0.52 |
| ▸ | NEK2 | P51955 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3319271 | 0.98 | ITGB3 (0.59) | ITGB3ITGA2BNOTUMKDM4ECYP2C19 | |
| Trifluoroacetic Acid SCHEMBL1648792 | 0.91 | ITGB3 (0.56) | ITGB3ITGA2BNOTUMKDM4ECYP2C19 | |
| SCHEMBL8838123 | 0.88 | ITGB3 (0.70) | ITGB3ITGA2BCYP2C19LSSAKR1C3 | |
| SCHEMBL2780304 | 0.84 | CYP3A4 (0.54) | ITGB3ITGA2BKDM4ELSSCHKA | |
| SCHEMBL3166233 | 0.84 | LSS (0.50) | ITGB3ITGA2BNOTUMLSSCHKA | |
| SCHEMBL16887557 | 0.84 | CYP2C9 (0.53) | ITGB3ITGA2BLSSCHKA | |
| SCHEMBL5223348 | 0.84 | LSS (0.50) | ITGB3ITGA2BNOTUMLSSCHKA | |
| SCHEMBL1222301 | 0.83 | NOTUM (0.79) | NOTUMKDM4ECYP2C19AKR1C3 | |
| Hydrochloric Acid SCHEMBL6798939 | 0.83 | LSS (0.49) | ITGB3ITGA2BLSSCHKAAKR1C3 | |
| SCHEMBL6769264 | 0.83 | LSS (0.50) | ITGB3ITGA2BNOTUMLSSCHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487505-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-08 | — | — | US | claimed |
| EP-1667993-B1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2015-07-01 | — | — | EP | claimed |
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | claimed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | claimed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| CN-119684140-A | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20250000797-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2025-01-02 | — | — | US | disclosed |
| CN-115175894-B | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| EP-4103542-A1 | NANOMATERIALS | Guide Therapeutics, LLC (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-4069675-A1 | NANOMATERIALS | Guide Therapeutics, LLC (US) | 2022-10-12 | — | — | EP | disclosed |
| US-5556977-A | ANTIAGGLOMERANTS FOR CELLS, ANTICOAGULANTS, ANTIISCHEMIC AGENTS USING PYRIDINYLPIPERAZINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-09-17 | — | — | US | disclosed |
| CN-1120334-A | Heterocyclic derivatives as platelet aggregation inhibitors | ZENECA LTD (GB) | 1996-04-10 | — | — | CN | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
| EP-0691959-A1 | HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-17 | — | — | EP | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022834-A1 | HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | ITGB3 1420/4885ITGA2B 1579/4885NOTUM 3873/4885 |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | PEPD, SERPINE1, PRSS1 | ITGB3 4003/4885ITGA2B 3663/4885NOTUM 384/4885 |
| US-20250000797-A1 | NANOMATERIALS | POLRMT, PHOSPHO1, FABP1 | ITGB3 1473/4885ITGA2B 1212/4885NOTUM 4381/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | ITGB3 938/4885ITGA2B 383/4885NOTUM 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.